Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 32.00 31.30 33.90 - 3,801 08:08:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 9.2 146

Ekf Diagnostics Share Discussion Threads

Showing 3176 to 3200 of 4425 messages
Chat Pages: Latest  129  128  127  126  125  124  123  122  121  120  119  118  Older
DateSubjectAuthorDiscuss
11/3/2021
14:11
Thanks Speedsgh...I absolutely concur!;-) As a consequence of the pandemic, diagnostics has been put firmly on the map and subsequently near the top of many priority lists in terms of investment, especially diagnostics being provided closer to the patient. The emergence and rapid growth in consumer-focused diagnostic businesses, as well as digital health revolutionising healthcare, are also going to provide long term growth trends. Whether it’s software as a medical device, artificial intelligence, health IT systems, wearable devices and telehealth systems etc – many investors will want exposure to the digital health revolution. And it bodes well for the IPO of Trellus Health...not to mention Renalytix!
wan
11/3/2021
12:47
Interesting to read the Investment Manager's view on the outlook for the diagnostics sub-sector in the BB Healthcare Trust (LSE:BBH) annual report... "Diagnostics (MSCI weighting: 2.2%, 2020 performance: +27.9%): A strong contender for the Marmite award in 2021. Many companies have enjoyed windfall returns from the emergence of COVID testing. Whilst this will continue for some time, the need should fade significantly on a multi-year view, begging the question of what the correct forward P/E should be for such earnings. As logical as this debate seems, there is a more pressing structural change going on that we have long anticipated and now expect to reap rewards from. That trend is the shifting of diagnostic capabilities closer to the patient; in the physician’s office or at the ward level in the hospital/clinic setting. The desire to ramp COVID testing capabilities has led to record placements of highly capable multiplex “boxes” during 2020. Even as COVID fades, these powerful tools have many other uses and the pull-though revenue opportunities are significant in our view. Rather like the all-powerful smartphone, you find these devices are not always used as initially intended by their purchasers but this does not matter to the likes of Apple. As long as these boxes are extant, they will drive some degree of consumables pull through. We continue to see increased usage of diagnostics as one of the key ‘mega-trends’ in the rapidly changing healthcare paradigm."
speedsgh
11/3/2021
07:56
Sequencing, sequencing, sequencing! PUBLISHED March 10, 2021 Thermo Fisher, PerkinElmer broaden COVID-19 mutation tracking products Dive Brief: Thermo Fisher Scientific and PerkinElmer have expanded their respective SARS-CoV-2 assays to help laboratories identify mutations associated with the rapidly emerging variants. Thermo Fisher launched a customizable panel of 22 PCR assays for identification of mutations to track virus variants that cause COVID-19. PerkinElmer will sell to labs a PCR assay that can detect mutations associated with B.1.1.7, B.1.351 and P.1 variants, the currently dominant strains, as well as a next-generation sequencing kit to detect all SARS-CoV-2 genetic changes. The products come days after a Rockefeller Foundation report found that the U.S. is currently conducting sequence-based surveillance for fewer than 1% of coronavirus cases, lagging far behind many countries. "The United States has been flying virally blind," the report warns. Dive Insight: Emergence of SARS-CoV-2 mutations has spurred a critical need to track and better understand their biology at the molecular level and determine how changes in the virus impact transmission and virulence, as well as the effectiveness of vaccines and therapeutics. However, genomic data is not being analyzed or shared fast enough to help public health authorities and scientists make informed decisions about relaxing precautions or adapting vaccines and treatments, according to the Rockefeller Foundation. PerkinElmer and Thermo Fisher are looking to provide laboratories with PCR assays that will enable surveillance of variants that are causing COVID-19 infections and to help them better select which mutations to track to limit their spread. With new and "very worrisome" mutations emerging in the U.S., the Rockefeller Foundation on Monday called for the creation of a national genomic surveillance system for gathering and sharing information on SARS-CoV-2 variants. "Until the U.S. is able to boost genomic surveillance, economically devastating shutdowns remain among the few effective tools to check rapid variant spread — an expensive and disruptive sledgehammer when a scalpel is needed," the report states. The Centers for Disease Control and Prevention in January awarded separate contracts to lab rivals Quest Diagnostics and LabCorp to provide genomic sequencing of samples of SARS-CoV-2 and study COVID-19 variants in an effort to improve the U.S. public health response. Financial terms of the contracts were not disclosed. The CDC's goal is to more than double the rate of genomic samples sequenced per week. However, the Rockefeller Foundation's action plan calls on the Biden administration to offer more pre-paid contracts for a fixed number of sequenced samples from state public health laboratories, universities and private companies. "These contracts can mandate specific turnaround times, ensure appropriate representation of all populations, and require information be shared by depositing sequences in designated databases," the plan states. Full story - hTTps://www.medtechdive.com/news/thermo-fisher-perkinelmer-broaden-covid-19-mutation-tracking-products/596457/
wan
11/3/2021
07:52
I note yesterday, that Quidel has guided conservatively for a significant softening in SARS-CoV-2 testing demand, but I also note they had a huge fourth quarter and thus shipped a lot of product in that quarter and that some "product in the channels that has not yet been used." The new guidance is also conservative, Bryant also said, as it does not incorporate a number of potential upsides. These upsides include increased demand from employers and schools for the firm's prescription use-only QuickVue self-test, a potential to increase manufacturing capacity faster, the possibility of selling tests outside of the US, a possible increase in infection prevalence, and less than perfect efficacy of vaccines sustaining testing demand. Full story - hTTps://www.360dx.com/pcr/quidel-guides-revenues-below-street-estimate-citing-softening-sars-cov-2-test-demand#.YEm01mj7SF4 Perhaps conversely, I note from yesterdays news regarding EKF's Executive Performance Bonus, the following closing statement - "The Company therefore remains very well capitalised to execute its plans and continues to generate strong operating and net cashflows. As previously announced, the Company expects to pay a dividend again in December 2021 and expects to implement a progressive dividend policy." So (and perhaps somewhat obvious), as of yesterday, EKF continues to generate strong operating and net cashflows. And expecting to implement a progressive dividend policy, would imply a continuation of such performance is also being predicted.
wan
11/3/2021
07:52
Wilmdav...I know that EKF/Longhorn have been involved with the development of saliva collection samples, which preferably still require inactivation. But, there are now lots of saliva collection options, and I am expecting saliva collection to be a longhorn option too.
wan
11/3/2021
07:24
This announcement from BATM sounds pretty good, about a saliva test. Does it represent a challenge to EKF? Https://www.investegate.co.uk/batm-advanced-comm--bvc-/rns/batm-launches-no-swab-saliva-based-covid-19-test/202103110700108689R/
wilmdav
10/3/2021
17:32
MG1982- can highly recommend the filter button- clears all the dross from an otherwise very decent board. And your last post got 6 ticks up - so as that market wizard Minervini would say, never go against the wisdom of the market :-)
firtashia
10/3/2021
15:38
Worthy of note - Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in... 10/03/2021 3:31pm PR Newswire (US) NEW YORK, March 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021 and ranked first in the Joint Ventures category. Kantaro launched in May 2020 in response to the COVID-19 pandemic to make a high-performing SARS-CoV-2 IgG antibody test created at Mount Sinai broadly accessible worldwide. "We are honored to be named one of the World's Most Innovative Companies by Fast Company and recognized for our work to ensure Kantaro antibody test kits are widely available to aid in the global battle against COVID-19," said Sara Barrington, chief commercial officer at Kantaro. Marketed as COVID-SeroKlir, the Kantaro test measures the presence and precise level of IgG antibodies — the same type of antibodies produced as part of the immune response to COVID-19. Unlike most other antibody tests, COVID-SeroKlir reports a numerical answer, not just a yes/no qualitative result. It can be used in any authorized clinical testing laboratory without the need for proprietary equipment. Kantaro also launched COVID-SeroIndex for research use only. Kantaro achieved a variety of milestones this year, including a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) to manufacture, sell and distribute the Kantaro tests at scale; receiving CE marking for COVID-SeroKlir and COVID-SeroIndex; and securing Emergency Use Authorization by the FDA for COVID-SeroKlir. Kantaro also established a global presence in the UK, Europe and South America through strategic partnerships with EKF Diagnostics, a global leader in diagnostic testing, and Atrys Health, a biomedical company dedicated to providing diagnostic services and medical treatments of excellence. The World's Most Innovative Companies is Fast Company's signature franchise and one of its most highly anticipated editorial efforts of the year. This year's Most Innovative Companies list honors 463 businesses from 29 countries that have found a way to be resilient in the past year and impact their industries and culture as a whole. It provides both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy. Full release - http://uk.advfn.com/stock-market/london/RENX/share-news/Kantaro-Biosciences-Named-to-Fast-Companys-Annual/84544929?xref=newsalert EKF is a distributor for the Kantaro antibody test kits
wan
10/3/2021
14:50
Just as a reminder (and partly in reference to my earlier post 1586), we have yet to see the financial effects from the following - New contract manufacturing opportunities at Boerne, Texas site for delivery in 2021 for five new customers: • Customer 1: RNA detection kits • Customer 2: CRISPR Human RNA depletion kit • Customer 3: Forensic kits • Customer 4: Next generation sequencing pathogen detection kits • Customer 5: Genome assembly and genetic variant detection kits Strong pipeline of opportunities to leverage capacity at Elkhart and South Bend, Indiana, facilities: • Oragenics: Enzymes for use in research • Ixcela: Food grade fermentation digestive protein • iGenomX: Molecular KOD enzyme (used in PCR) Not to mention the completion of Quo-Test cartridge registration in China expected by December 2020 or early 2021, with negotiations apparently already underway with potential distributors to sell analysers and tests in 2021.
wan
10/3/2021
13:29
You have to love the plc world. One can bet their last pennies that senior managers will always be very able to look after themselves.
tongosti
10/3/2021
10:20
Cheers wan, an impressive product for a globally prevalent need.
rivaldo
10/3/2021
07:17
9th March 2021 EKF globally launches STAT-Site® WB β-ketone and glucose handheld analyzer EKF Diagnostics, the global in vitro diagnostics company, announces the global launch of its STAT-Site® WB handheld analyzer which delivers β-ketone and glucose measurements from whole blood in seconds. This follows the securing of its CE mark certification alongside its FDA CLIA-waiver, meaning that the portable, dual-purpose analyzer is ideal for professional use in the management of diabetes patients. The STAT-Site® WB is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or BHB) and glucose in whole blood taken from capillary or venous samples. The easy-to-use analyzer is reagent free, utilizing two different test strips to deliver results in just 10 seconds for β-ketones and 5 seconds for glucose. This enables clear and comprehensive management of diabetes patients displaying early symptoms of ketosis, ensuring their rapid treatment and subsequent regular monitoring. βHB is used to aid the diagnosis and monitoring of patients with ketosis (diabetic ketoacidosis or DKA). As β-HB accounts for 78% of all ketones present in the body, and is the first to appear during ketosis, it provides the clearest indication of a patient’s condition before and after treatment. The STAT-Site WB is calibrated to the gold standard Liquicolor Beta-Hydroxybutyrate method, meaning that it delivers laboratory accurate results within seconds near to the patient. Further ensuring results accuracy, the handheld analyzer is simple and intuitive to use, even for inexperienced users. The STAT-Site WB auto-starts when a test strip is inserted and will also automatically detect if it is a BHB or glucose test to be undertaken. Just 1 µL of whole blood is required for direct analysis and the system will also detect and alert if insufficient blood is available. An automatic strip ejection function ensures that cross contamination is avoided. Also making it ideal for remote testing, the analyzer uses two 1.5V AAA alkaline batteries which are easy to obtain and replace, whilst test strips are available individually foil wrapped or in a vial with a shelf life of six months once opened. Results are clearly displayed on a large LCD screen interface with capacity for up to 400 measurements to be stored on the system – these can be downloaded via a mini USB lead. “STAT-Site WB provides an affordable, easy-to-use technology that can help to reduce the cost of long-term healthcare of the growing diabetic and pre-diabetic population globally,” said Gavin Jones, Head of Product Management, EKF Diagnostics. “Having direct access to lab quality β-ketone and glucose near patient results ensures the practitioner has the essential data needed to make informed clinical or lifestyle decisions in seconds.” Full release - hTTps://www.ekfdiagnostics.com/ekf-globally-launches-stat-site-wb-ketone-and-glucose-handheld-analyzer.html To put this global launch into some context in terms of importance and need - Increasing Hospitalizations for DKA: A Need for Prevention Programs Priyathama Vellanki and Guillermo E. Umpierrez Diabetes Care 2018 Sep Diabetic ketoacidosis (DKA) is a diabetes emergency associated with high morbidity in patients with diabetes (1). In patients with type 1 diabetes, DKA can occur at new onset of diabetes but can also recur due to lack of insulin use and precipitating causes such as infection. DKA is a hallmark of type 1 diabetes; however, DKA is increasingly recognized in patients with type 2 diabetes (2). In contrast to patients with type 1 diabetes who require life-long insulin therapy, most patients with type 2 diabetes who present with DKA can recover insulin secretion and maintain glycemic control with oral antidiabetes medications (3). While inpatient mortality rates for DKA are generally very low, <1% in the U.K. (4) and in the U.S. (5), DKA is the leading cause of mortality among children and young adults with type 1 diabetes, accounting for ∼50% of all deaths in this population (1). In addition, rates vary substantially based on health care setting; a recent analysis conducted in India reported that up to 30% of hospitalized DKA cases result in inpatient death (6). hTTps://care.diabetesjournals.org/content/41/9/1839
wan
09/3/2021
13:54
I think ppl are right. I should filter you. I appreciate bear cases I don't appreciate trolls that can't get their message across in simple language. Tong is now filtered
mg1982
09/3/2021
13:52
Ignorance is bliss. Long this may continue - unless market boats get heavily tipped on one side here and there, how can one make money?Love these boards.
tongosti
09/3/2021
13:50
MG1982 - suggest you just filter her/him like most of us do then you will not provoke yet more replies tongosti 9 Mar '21 - 10:34 - 1593 of 1595 (Filtered) MG1982 9 Mar '21 - 13:12 - 1594 of 1595 In English pls Tong? Thanks tongosti 9 Mar '21 - 13:47 - 1595 of 1595 (Filtered)
sharw
09/3/2021
13:47
It's not one's fault that he/she may have never worked in the industry. What is a problem (for that particular individual of course - whether they know it or not) is that if he/she does not understand a very basic comment (incidentally with this being number 1 question a smart portfolio manager asks before initiating a position, ANY position) - then one shouldn't gamble their savings in the market before they go back to the drawing board.
tongosti
09/3/2021
13:12
In English pls Tong? Thanks
mg1982
09/3/2021
10:34
et action 101Over the longer term, it's fundamentals that drive prices. However they have a habit of showing in the price way before they show in fundamentals. This is precisely where most fundamentally driven players get lost - as understanding such a key property of markets inevitably means that one needs to go way beyond fundamentals (and shorten their time horizons to accommodate risk management) to make (and protect their) money. Any wonder the very top - folks were laughing at doctors orders then - took place the day the Pfizer vaccine was announced? Going forward (not that many on here can or are willing to think about it, unfortunately) the most relevant question is: what exactly is Mr Market currently discounting?
tongosti
09/3/2021
10:18
This one? https://www.proactiveinvestors.co.uk/companies/news/943260/sourcebio-international-score-high-with-fixture-for-england-rugby-coronavirus-testing-contract-943260.html
jacks13
09/3/2021
10:06
This interview with #SBI's CEO is also very relevant to #EKF. Testing is here to stay at least for calendar year 2021.
mg1982
09/3/2021
07:24
Could be any minute now... Bear with him chaps.
tongosti
08/3/2021
15:52
GG I thought you had quit smoking (in the sequel). Went back to it again?
tongosti
08/3/2021
13:02
ANA is the best UK cannabis stock Share price 1.1p Only £6.4m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued (£6.4m mkt cap) Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every cannabis co Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too Worth getting in on the ground floor imho. hTTps://businesscann.com/work-on-12m-medicinal-cannabis-cultivation-facility-held-up-by-covid-19-uk-travel-ban/ hTTps://anandadevelopments.com/tiamat-agriculture-ltd/
gordan ghetto
07/3/2021
22:09
Brilliant. Am sure every one on this board is well versed into the technicalities of the article you have copied and pasted.
tongosti
07/3/2021
17:29
I have been catching up in a few areas that I have neglected. In 2018 EKF Diagnostics signed an exclusive agreement with Oragenics, Inc. (NYSE American: OGEN), a Florida-based biopharmaceutical company, for the manufacturing of Oragenics’ lantibiotic bulk drug substances in the United States. I note the following Presentation and recent news flow - • Lantibiotics are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacterial strains to attack competing bacterial strains • Platform: >700 lantibiotic structures created, potentially generating a pipeline of new compounds • Platform provides potential for development in multidrug resistant infections: − Methicillin Resistant Staphlococcus aureus (MRSA) − Vancomycin Resistant Enterococci (VRE) − Virulent Clostridium difficile − Gram(-) infections Novel class of peptide antibacterial compounds called Lantibiotics • Activity against a variety of MDR infections, believed to be the next human health crisis • Lead lantibiotic OG716 addresses C. difficile – a significant infection identified by the CDC. They estimate filing for FDA IND (Investigational New Drug (IND) Application) in Q2 2021, but this was subject to having adequate available capital to complete requisite studies. Presentation November 2020, Lantibiotics page 18 onwards - hTTps://d1io3yog0oux5.cloudfront.net/_3163672321476757073a795d523eea69/oragenics/db/224/647/pdf/14558382v1+-+Oragenics+Investor+Deck+11+14+20+AGP+FINAL.pdf February 12, 2021 TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics&rdquo; or the “Company&rdquo;) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Officer of Oragenics, said, “We are delighted that we were able to raise capital to fund our operations through a number of anticipated key value-creating milestones towards the initiation of the Phase 2 clinical trial of our SARS CoV-2 vaccine, Terra CoV-2. In addition, we will be able to advance our lantibiotics program, which is directed at solving the problem of multidrug-resistant organisms. hTTps://www.oragenics.com/news-media/press-releases/detail/123/oragenics-announces-recent-capital-raise-and-warrant Oragenics are thus funded to advance and file for FDA IND, and I assume they will require further product to support that. And if that filing is ultimately successful, one can imagine that very large bulk volumes will be required to address such an important issue as antibiotic-resistant infections (this might also be of particular interest to ESG Investment Funds?)
wan
Chat Pages: Latest  129  128  127  126  125  124  123  122  121  120  119  118  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220701 08:55:57